Filing Details
- Accession Number:
- 0001415889-24-004718
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-21 21:51:28
- Reporting Period:
- 2024-02-17
- Accepted Time:
- 2024-02-21 21:51:28
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1348911 | Kalvista Pharmaceuticals Inc. | KALV | Pharmaceutical Preparations (2834) | 200915291 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1691090 | P. Edward Feener | C/O Kalvista Pharmaceuticals, Inc. 55 Cambridge Parkway, Suite 901E Cambridge MA 02142 | Chief Scientific Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-02-17 | 18,788 | $0.00 | 90,445 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-02-20 | 8,397 | $14.11 | 82,048 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-20 | 19,591 | $14.04 | 62,457 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-20 | 300 | $14.72 | 62,157 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Unit | Disposition | 2024-02-17 | 1,774 | $0.00 | 1,774 | $0.00 |
| Common Stock | Restricted Stock Unit | Disposition | 2024-02-17 | 2,430 | $0.00 | 2,430 | $0.00 |
| Common Stock | Performance Stock Units | Disposition | 2024-02-17 | 7,292 | $0.00 | 7,292 | $0.00 |
| Common Stock | Performance Stock Units | Disposition | 2024-02-17 | 7,292 | $0.00 | 7,292 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 15,964 | No | 4 | M | Direct | ||
| 17,014 | No | 4 | M | Direct | ||
| 7,292 | No | 4 | M | Direct | ||
| 21,875 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit ("RSU") and performance stock unit ("PSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
- The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs and PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.7506 to $14.1289 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 20, 2023.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.66 to $14.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on August 17, 2022, subject to continued service through each vesting date.
- 1/12th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 17, 2022, subject to continued service through each vesting date.
- Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on June 8, 2023. Each PSU represents a contingent right to receive one share of Issuer Common Stock upon the Issuer's achievement of performance metric goals ("Performance Metrics"). 1/4th of the total number of shares subject to the PSU shall vest on each quarterly anniversary of the Vesting Commencement Date of August 17, 2023, upon Performance Metrics achieved, subject to continued service through each vesting date.
- Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on January 10, 2024. Each PSU represents a contingent right to receive one share of Issuer commonstock upon the Issuer's achievement of Performance Metrics. 1/4th of the total number of shares subject to the PSU shall vest on each quarterly anniversary of the Vesting Commencement Date ofFebruary 17, 2024, upon Performance Metrics achieved, subject to continued service through each vesting date.
Billionaire Hedge Funds
